Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
Genetic Vaccine Development for Infectious Diseases Summit - May 2021 - Digital Event

Genetic Vaccine Development for Infectious Diseases Summit - May 2021 - Digital Event

Categories

Date of beginning

Tuesday, 18 May 2021

Duration

3 days

City

Online

Country

United States

Contact

Customer Service

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Expected participants

1000

Memo

The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. A combination of urgent need, unprecedented investments, and advances in genetic engineering has allowed what was once mere speculation to become not only our reality, but our future. With pandemic vaccines now launching at record speeds, the first Genetic Vaccine Development for Infectious Diseases Summit will focus on overcoming the translational and clinical challenges of developing genetic vaccines targeting infectious diseases, including Influenza, Lassa fever, Ebola, MERS, HIV, Zika, and COVID-19. Tickets https://go.evvnt.com/733342-0?pid=5569Brochure https://go.evvnt.com/733342-3?pid=5569 Prices:Conference Only USD 2199.00,Conference + Focus Day USD 2898.00 Speakers: Stefanie Krumm, PhD Associate Director, Infectious Disease Vaccines BioNTech, Andreas Kuhn, PhD Sr. VP, RNA Biochemistry & Manufacturing BioNTech, Philip Dormitzer, PhD Vice President & Chief Scientific Officer: Viral Vaccines Pfizer, Johan Vekemans, PhD Global Clinical Head, SARS-CoV-2 Vaccine AstraZeneca, Ali Fattom, PhD Chief Scientific Officer Blue Willow Biologics, Stefan Mueller, PhD COVID-19 Program Lead & Vice President Pre-Clinical Development CureVac, Lidia Oostvogels, PhD VP Area Head Infectious Diseases CureVac, Jesse Erasmus, PhD Director of Virology HDT Bio, Norman Begg, PhD Former Chief Medical Officer GSK Vaccines, Jean Boyer, PhD VP Analytical Science Inovio, Kate Broderick, PhD Sr. VP, R&D Inovio, Jason DeHart, PhD Senior Principal Scientist, RNA & Targeted Therapeutics Janssen, Luis Brito, PhD Senior Director, Formulation Science Moderna, Jacqueline Miller, MD Sr. VP Therapeutic Area Head, Infectious Diseases Moderna, Dong Yu Pre-clinical R&D GSK Vaccines, Jakob Cramer, PhD Head of Clinical Development CEPI, Larry Corey, PhD President & Director Emeritus Fred Hutchinson Cancer Research Center, Luk Vandenberghe, PhD Director Grousbeck Gene Therapy Center, Galit Alter, PhD Professor of Medicine Harvard Medical School, Amesh Adalja, PhD Senior Scholar John Hopkins Centre for Health Security, Olivia Merkel, PhD Professor Ludwig-Maximilians-Universit√§t M√ľnchen, Ronit Satchi-Fainaro, PhD Head, Cancer Research and Nanomedicine Laboratory Tel Aviv University, Ami Patel, PhD Research Assistant Professor The WISTAR Institute, Mohadeseh Hasanpourghadi, PhD Post Doctoral Fellow The WISTAR Institute, Hildegund Ertl, PhD Professor The WISTAR Institute, Matthias Schnell, PhD Professor & Chair, SKMC Microbiology & Immunology Thomas Jefferson University, Stanley Plotkin, PhD Professor Emeritus of Virology University of Pensylvania, Louis Picker, PhD Associate Director & Professor Vaccine and Gene Therapy Institute, OHSU, Dan Barouch , PhD., MD., William Bosworth Castle Professor of Medicine Harvard Medical School, Susanne Rauch Principal Scientist CureVac Time: On Tuesday May 18, 2021 at 8:00 am (ends Thursday May 20, 2021 at 5:00 pm)